Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease
Open Access
- 17 November 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 21 (5), 1124-1137
- https://doi.org/10.1093/hmg/ddr541
Abstract
There is substantial evidence that impairment of peroxisome proliferator-activated receptor (PPAR)-γ-coactivator 1α (PGC-1α) levels and activity play an important role in Huntington's disease (HD) pathogenesis. We tested whether pharmacologic treatment with the pan-PPAR agonist bezafibrate would correct a deficiency of PGC-1α and exert beneficial effects in a transgenic mouse model of HD. We found that administration of bezafibrate in the diet restored levels of PGC-1α, PPARs and downstream genes to levels which occur in wild-type mice. There were significant improvements in phenotype and survival. In the striatum, astrogliosis and neuronal atrophy were attenuated and numbers of mitochondria were increased. Bezafibrate treatment prevented conversion of type I oxidative to type II glycolytic muscle fibers and increased the numbers of muscle mitochondria. Finally, bezafibrate rescued lipid accumulation and apparent vacuolization of brown adipose tissue in the HD mice. These findings provide strong evidence that treatment with bezafibrate exerts neuroprotective effects which may be beneficial in the treatment of HD.Keywords
This publication has 60 references indexed in Scilit:
- Impaired PGC-1α function in muscle in Huntington's diseaseHuman Molecular Genetics, 2009
- Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegenerationCell Metabolism, 2006
- Oxidative Damage in Huntington's Disease PathogenesisAntioxidants and Redox Signaling, 2006
- Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and NeurodegenerationCell, 2006
- Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional CoactivatorsCell, 2006
- Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dGNeurology, 2006
- PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic SteatosisPLoS Biology, 2005
- Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null MiceCell, 2004
- Huntington DiseaseJournal of Neuropathology and Experimental Neurology, 1998
- Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic MiceCell, 1996